Turkey’s medical-tourism market reached an estimated $3.5 billion in 2025, with hair transplantation accounting for 51.9% of ...
CHO expression and rapid characterization help close the gap between computational design and experimental validation · ...
Gilead Sciences has picked up a new inflammatory disease program from China’s PepStar Therapeutics to pair with the Phase 2 ...
A combination of Tango Therapeutics’ vopimetostat and Revolution Medicines’ recently approved Rasonque led to a response rate ...
First reported clinical evaluation of an allogeneic CD19-directed CAR T-cell therapy in progressive MS demonstrated an ...
October 23, 2026) - Global Hemp Group Inc. (CSE: GHG) (FSE: GHG0) (OTC PINK: GBHPF) ("GHG" or the "Company") is pleased to ...
RNAi specialist Alnylam Pharmaceuticals will advance the Huntington’s disease drug brezosiran into a placebo-controlled study ...
Following the withdrawal of billions of dollars in investments from Boehringer Ingelheim and Eli Lilly, German lawmakers have ...
After cardiac safety signals led to a full clinical hold on Aardvark Therapeutics’ studies of ARD-101, the biotech conducted ...
A new proposal from the U.S. government seeking to address investment in Chinese biotech as a matter of national security ...
Financing will support Star’s next phase of growth, including advancement of current preclinical programs into the clinic and ...
Completion of light dose-escalation Part A of Phase 1 study identifies regimen for further evaluation in Part B, supporting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results